Please note: The information displayed on this page might be outdated.
Taiwan Liposome Company: TLC is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine proprietary lipid-assembled drug delivery platforms with approved active pharmaceutical ingredients (APIs). TLC's extensive experience with liposome science allows fast onset speed, prolonged benefit duration, and improved API concentrations at target tissues while decreasing unwanted systemic exposures. Product candidates span across pain (TLC599 for osteoarthritis pain (Ph2 complete, Ph3 2H 2019), TLC590 for postsurgical pain (reported Ph1/2 top line, Ph2 initiated)), ophthalmology (TLC399 for macular edema (Ph2)), and oncology (TLC178 for rhabdomyosarcoma (Ph1/2)). All programs expected to be in late or pivotal stage by the end of 2020.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Ophthalmology, Pain
Biotechnology, Specialty Pharmaceutical
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Drug Delivery
2F, 3 Yuanqu Street, Nangang District
Taipei , 11503

Company Participants at Class of 2018 Biotech IPO Investor Day

  • George Yeh, President

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.